Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients

被引:3
作者
Chen, Pan [1 ]
Xu, Xuan [1 ]
Liu, Longshan [2 ]
Wu, Jingjing [1 ]
Li, Jingjie [3 ]
Fu, Qian [2 ]
Chen, Jie [1 ]
Wang, Changxi [2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pharm, 58 Zhong Shan Er Lu, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplantat Ctr, 58 Zhong Shan Er Lu, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Ctr Reprod Med, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Mizoribine; Renal transplantation; Pharmacokinetics; Immunosuppression; HIGH-DOSE MIZORIBINE; MYCOPHENOLATE-MOFETIL; BLOOD-LEVEL; BIOAVAILABILITY; BREDININ; SAFETY;
D O I
10.1007/s00228-018-2584-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PurposeMizoribine (MZR) is an immunosuppressive agent with extensive inter-individual differences in pharmacokinetics (PK). Here, we investigated the PK characteristics of MZR in renal transplant recipients and gave equations for prediction of some critical PK parameters.MethodsA total of 40 renal transplant recipients participated in this prospective study and were administered MZR orally twice daily in the range of 1.1-8.9mgkg(-1)day(-1). Steady-state concentrations of MZR were detected before (0h) and 0.5, 1, 2, 3, 4, 5, 6, 8, and 12h after administration by high-performance liquid chromatography method. Another 38 patients with newly detected trough concentration (C-0) were enrolled to validate the obtained C-0 predictive equation.ResultsSignificant inter-individual differences in MZR PK parameters were observed. Patients with decreasing creatinine clearance rate (CCr) had significantly decreased terminal elimination rate constant (k(el)) and apparent total body clearance (Cl/F), while other PK parameters including apparent terminal half-life (t(1/2)), peak time (T-max), peak concentration (C-max), area under the curve (AUC(0-12h)), apparent volume of distribution (V/F), and mean residence time (MRT) were significantly increased. Correlation coefficients between AUC(0-12h) and C-0/C-max were 0.894 and 0.916, respectively (both p<0.001). A serum creatinine (SCr)-based predictive C-0 equation [C-0=(2.160xSCr-54.473)xDose] was established and validated by C-0 from another 38 patients. Besides, significant linear correlations between k(el)/t(1/2) and CCr were also found (r(2)=0.668 and 0.484, respectively), and equations predicting k(el)/t(1/2) were also obtained (k(el)=0.015+0.002xCCr, t(1/2)=13.601-0.139xCCr).ConclusionsRenal function plays as an essential factor that contributes to great inter-individual MZR PK variation. Both C-0 and C-max are suitable for evaluating MZR exposure in the body. SCr could be applied to predict C-0 and t(1/2) of MZR.
引用
收藏
页码:363 / 369
页数:7
相关论文
共 22 条
  • [1] Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis
    Abe, Y
    Tsuji, Y
    Hisano, M
    Nakada, M
    Miura, K
    Watanabe, S
    Odajima, Y
    Iikura, Y
    [J]. PEDIATRICS INTERNATIONAL, 2004, 46 (05) : 597 - 600
  • [2] Pharmacokinetic study of mizoribine in child-onset glomerulonephritis
    Abe, Yoshifusa
    Mikawa, Takeshi
    Fuke, Toshiya
    Hisano, Masataka
    Tsuji, Yuichiro
    Watanabe, Shuichiro
    Itabashi, Kazuo
    [J]. PEDIATRICS INTERNATIONAL, 2008, 50 (05) : 615 - 619
  • [3] Effect of Genetic Polymorphisms of SLC28A1, ABCG2, and ABCC4 on Bioavailability of Mizoribine in Healthy Japanese Males
    Fukao, Miki
    Ishida, Kazuya
    Sakamoto, Takuya
    Taguchi, Masato
    Matsukura, Hiroyoshi
    Miyawaki, Toshio
    Hashimoto, Yukiya
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (05) : 538 - 543
  • [4] Mizoribine requires individual dosing due to variation of bioavailability
    Fuke, Toshiya
    Abe, Yoshifusa
    Hibino, Satoshi
    Takeshi, Mikawa
    Saito, Takako
    Sakurai, Shunsuke
    Watanabe, Shuichiro
    Murayama, Jun-Ichiro
    Itabashi, Kazuo
    Nakano, Yasuko
    [J]. PEDIATRICS INTERNATIONAL, 2012, 54 (06) : 885 - 891
  • [5] IHARA H, 1994, TRANSPLANT P, V26, P2029
  • [6] Ihara H, 1996, TRANSPLANT P, V28, P1321
  • [7] Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males
    Ishida, Kazuya
    Fukao, Miki
    Watanabe, Hitomi
    Taguchi, Masato
    Miyawaki, Toshio
    Matsukura, Hiroyoshi
    Uemura, Osamu
    Zhang, Zufei
    Unadkat, Jashvant D.
    Hashimoto, Yukiya
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (01) : 75 - 80
  • [8] KOKADO Y, 1994, TRANSPLANT P, V26, P2111
  • [9] Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection
    Liu, D
    Kobayashi, T
    Nagasaka, T
    Yokoyama, I
    Ma, Y
    Miwa, Y
    Kuzuya, T
    Morozumi, K
    Oikawa, T
    Shimano, Y
    Takeuchi, O
    Uchida, K
    Nakao, A
    [J]. TRANSPLANT INTERNATIONAL, 2005, 18 (04) : 401 - 407
  • [10] The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease
    Nagai, Takuhito
    Uemura, Osamu
    Kaneda, Hisashi
    Ushijima, Katsumi
    Ohta, Kazuhide
    Gotoh, Yoshimitsu
    Satomura, Kenichi
    Shimizu, Masaki
    Fujieda, Mikiya
    Morooka, Masashi
    Yamada, Takuji
    Yamada, Masayoshi
    Wada, Naohiro
    Hashimoto, Yukiya
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (05) : 884 - 888